Aptevo Therapeutics Inc.
APVO· Nasdaq
APVOAptevo Therapeutics Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001193125-26-350559
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$6.36M | -$6.20M | -$5.88M | -$7.95M |
| EPS Diluted | -$5.31 | -$151.29 | -$1,236.96 | -$53.95 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
